Lancet Infectious Diseases Impact Factor

The first signal is prestige. Lancet Infectious Diseases is sitting at the top of the Infectious Diseases category.

The second signal is normalized strength. The JCI is extremely high, which matters because infectious-disease citation cultures vary widely across epidemiology, virology, antimicrobial resistance, and clinical therapeutics.

The third signal is recency. The five-year JIF of 26 is below the current JIF, which suggests the latest two-year citation window remains stronger than the longer window even after the pandemic-era peak.

Use the JCR row above for the official impact-factor claim. The Scopus impact-score series below is a directional companion, useful for judging how much of the post-pandemic infectious-disease citation signal is normalizing.

Directionally, the open citation signal is down from 9.72 in 2023 to 8.68 in 2024. That is not surprising for an infectious-disease title after the extraordinary pandemic citation cycle. The more important point is that the official JCR signal remains extremely strong.

The common mistake is to treat Lancet Infectious Diseases as a generic high-impact infectious-disease destination.

That misses the actual editorial question. This journal wants work with broad clinical or public-health consequence, not only a good study in an infectious-disease niche.

Papers often miss here when they are:

• strong but too local in geography or health-system context

• methodologically sound without a clear practice or policy implication

• too focused on one narrow pathogen lane without broader consequence

• better suited to a specialty ID or microbiology journal

The number says the journal is elite. It does not say the journal is a home for every good infectious-disease paper.

For manuscripts targeting Lancet Infectious Diseases, three patterns show up repeatedly.

In our infectious-disease review work, the manuscripts that survive this level of screening usually make the cross-setting practice or policy consequence obvious before the methods detail begins.

The study is good, but too local. Single-system and single-setting papers often underestimate how much the journal cares about broader relevance.

The abstract does not make the practice implication obvious enough. Editors read quickly, and hidden consequence is often treated as weak consequence.

The manuscript is better owned by a specialty journal. Many sound papers belong in CID, JID, or a pathogen-specific venue because the true readership is narrower than the authors claim.

If that sounds familiar, a Lancet Infectious Diseases submission readiness review is usually more valuable than another cosmetic revision.

The current publisher-facing materials add a useful non-JCR signal: the journal markets itself as a world-leading infectious-disease journal and cites a CiteScore of 42.6 with a strong Scopus infectious-disease position. If a publisher widget still shows 31.0, treat it as the prior JIF rather than overriding the current 2026 JCR release.

That matters because it shows the journal is not only highly cited by JCR logic. It is also built around broad infectious-disease visibility across the Scopus ecosystem.

The practical implication is that the journal rewards papers that travel well across clinicians, researchers, and policy audiences.

In our pre-submission review work on Lancet Infectious Diseases submissions, the impact factor rarely answers the real targeting question by itself. The manuscripts that use the metric well usually pair the 29.4 signal with a clear argument about clinical consequence, global practice relevance, and implementation. The manuscripts that use it poorly treat the number as permission to submit any strong infectious-disease paper to a Lancet-family title.

High metric, local evidence mismatch is the pattern we see most often. A hospital-network cohort, regional AMR surveillance study, or vaccine-effectiveness analysis may be valuable and publishable, but Lancet Infectious Diseases needs the abstract and methods to show why the finding travels beyond the source system. If the generalizability case depends on one discussion paragraph, the impact factor is flattering the target rather than validating it.

Citation prestige replacing endpoint discipline is another repeat problem. Authors cite the journal's impact factor, but the manuscript's endpoint, sample size, follow-up window, or comparator cannot support a practice-changing claim. That mismatch is visible before peer review. The methods section has to carry the same level of ambition as the cover letter.

Metric-owner confusion across the cluster can also weaken trust. The broad Lancet Infectious Diseases journal hub should answer fit, while this page owns the current JIF, five-year JIF, rank context, and how to interpret the number. Submission mechanics belong on the Lancet Infectious Diseases submission guide, and timing belongs on the review-time page.

Our analysis of current metric-owner data, the journal hub, public publisher surfaces, the Editorial Manager route, and recent Crossref records supports the 29.4 current value while explaining the prior 31.0 publisher snippet. The practical test is whether the manuscript's abstract, endpoint hierarchy, main table, and Research in Context framing justify using a 29.4-JIF target. If those components still read as local, exploratory, or specialty-only, the metric is telling you the journal is elite, not that the paper belongs there.

The impact factor does not tell you whether the result generalizes, whether the policy or practice consequence is visible enough, or whether the true audience is actually a more specialized infectious-disease journal.

Those are the real editorial screens.

Waiting on a decision? The Lancet Infectious Diseases Under Review status guide explains what the status means at each stage and when nudging the editor makes sense.